Innate Pharma announces revenue for the first three months of 2014 and updates on its cash Position
Highlights from Innate Pharma's R&D update
Number of shares and voting rights of Innate Pharma as at April 4, 2014
Start of cohort expansion of Phase I clinical trial testing the combination of lirilumab and nivolumab in selected solid tumors
Outcome of Annual General Meeting of March 27, 2014
Number of shares and voting rights of Innate Pharma as at March 24, 2014
R&D Update on April 10, 2014 in New York
Number of shares and voting rights of Innate Pharma as at March 7, 2014
Innate Pharma continues Phase II trial with lirilumab as planned, following Data and Safety Monitoring Board recommendation
Innate Pharma to hold its annual general meeting of shareholders on March 27, 2014
